Le Lézard
Classified in: Ebola virus, Health, Science and technology
Subjects: PDT, TRI

Integral Molecular Launches Transgene Protein Engineering Platform to Address Challenges in Gene Therapy

PHILADELPHIA, July 30, 2021 /PRNewswire/ -- Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements.

GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients.

The GeneCanvas platform is built on Integral Molecular's 20 years of experience in optimizing the most challenging and structurally complex proteins known, such as GCPRs, ion channels, transporters, and viral envelopes. GeneCanvas incorporates the company's proprietary high-throughput mutagenesis and human cell screening platforms that enable the creation and screening of large libraries of variants, which have been used in hundreds of projects internally and for partners.

"Our scientists bring an unrivaled mix of deep expertise in protein engineering, cell biology, and virology to develop a customized strategy for each engineering challenge," said Joseph Rucker, PhD, Vice-president of Research and Development at Integral Molecular.

Integral Molecular showcased its GeneCavas platform during the digital BIO International Convention that took place in June 2021.

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Communications  

SOURCE Integral Molecular

These press releases may also interest you

at 20:35
Lobe Sciences Ltd. ("Lobe" or the "Company") is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion ("mTBI") and post-traumatic stress disorder ("PTSD"),...

at 20:00
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, released...

at 19:29
The Honourable Carolyn Bennett, Minister of Crown-Indigenous Relations, the Honourable Patty Hajdu, Minister of Health, the Honourable Marc Miller, Minister of Indigenous Services and the Honourable Daniel Vandal, Minister of Northern Affairs, issued...

at 18:42
AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTAtm (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor...

at 18:20
Element Blue, a leader in intelligent automation specializing in the healthcare sector, has retained its status as a UiPath Gold Partner. In 2017 Element Blue became a Gold Partner with UiPath ? the leading enterprise Robotic Process Automation (RPA)...

at 18:19
StemExpress announces it will be providing tours of its groundbreaking pandemic response Mobile Laboratory, Thursday, September 30th at its Rockville, Maryland location. Guests and press are invited to schedule a private tour to learn about this...

News published on 30 july 2021 at 07:05 and distributed by: